Structure-Guided Design and Synthesis of Pyridinone-Based Selective Bromodomain and Extra-Terminal Domain (BET)-First Bromodomain (BD1) Inhibitors
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.3c01837 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Yangfeng Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: UICentre (Drug Discovery@UIC), University of Illinois at Chicago, 833 S Wood Street, Chicago, Illinois 60612, United States. Hauptthemen laut MEDLINE: Transcription Factors, Nuclear Proteins. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: NCRR NIH HHS, NIAID NIH HHS, Chicago Biomedical Consortium.
Abstract (Originalsprache)
The bromodomain and extra-terminal domain (BET) proteins are epigenetic readers, regulating transcription via two highly homologous tandem bromodomains, BD1 and BD2. Clinical development of nonselective pan-BD BET inhibitors has been challenging, partly due to dose-limiting side effects such as thrombocytopenia. This has prompted the push for domain-selective BET inhibitors to achieve a more favorable therapeutic window. We report a structure-guided drug design campaign that led to the development of a potent BD1-selective BET inhibitor, 33 (XL-126), with a Kd of 8.9 nM and 185-fold BD1/BD2 selectivity. The high selectivity was first assayed by SPR, validated by a secondary time-resolved fluorescence energy transfer assay, and further corroborated by BROMOscan (∼57-373 fold selectivity). The cocrystal of 33 with BRD4 BD1 and BD2 demonstrates the source of selectivity: repulsion with His437 and lost binding with the leucine clamp. Notably, the BD1 selectivity of BET inhibitor 33 leads to both the preservation of platelets and potent anti-inflammatory efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- UICentre (Drug Discovery@UIC), University of Illinois at Chicago, 833 S Wood Street, Chicago, Illinois 60612, United States.
- Department of Pharmaceutical Sciences, University of Illinois College of Pharmacy, University of Illinois at Chicago, 833 S Wood Street, Chicago, Illinois 60612, United States.
- Research Resources Center, University of Illinois at Chicago, Chicago, Illinois 60612, United States.
- Department of Pharmacology & Toxicology, University of Arizona, Tucson, Arizona 85721, United States.
ORCID-Profile: Yangfeng Li, Gregory R J Thatcher, Rui Xiong
Förderung
- NCRR NIH HHS
- NIAID NIH HHS
- Chicago Biomedical Consortium
- National Institutes of Health
- G1 Therapeutics
Zitieren
APA
Li, Y., Shen, Z., Ratia, K., Zhao, J., Huang, F., Dubrovyskyii, O., Indukuri, D., Fu, J., Lozano Ramos, O., Thatcher, G. R. J., & Xiong, R. (2024). Structure-Guided Design and Synthesis of Pyridinone-Based Selective Bromodomain and Extra-Terminal Domain (BET)-First Bromodomain (BD1) Inhibitors. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c01837
Vancouver
Li Y, Shen Z, Ratia K, Zhao J, Huang F, Dubrovyskyii O, et al. Structure-Guided Design and Synthesis of Pyridinone-Based Selective Bromodomain and Extra-Terminal Domain (BET)-First Bromodomain (BD1) Inhibitors. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.3c01837
BibTeX
@article{Li2024,
author = {Li, Yangfeng and Shen, Zhengnan and Ratia, Kiira and Zhao, Jiong and Huang, Fei and Dubrovyskyii, Oleksii and Indukuri, Divakar and Fu, Jiqiang and Lozano Ramos, Omar and Thatcher, Gregory R J and Xiong, Rui},
title = {Structure-Guided Design and Synthesis of Pyridinone-Based Selective Bromodomain and Extra-Terminal Domain (BET)-First Bromodomain (BD1) Inhibitors},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.3c01837}
}
EUVIMED